Care Access Research /ID# 218476 — Hoboken, New Jersey

Care Access Research /ID# 218476 is a clinical research site located in Hoboken, New Jersey, United States 07030-2757.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Care Access Research /ID# 218476 has participated in 1 clinical trials.

Therapeutic areas: Atopic Dermatitis.

Sponsors: AbbVie.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Hoboken

Browse all research sites in New Jersey · View every site in Hoboken

• University Reproductive Associates
• Hoboken University Medical Center (MSSM satellite site)
• Care Access Hoboken
• Novo Nordisk Investigational Site
• Hudson Dermatology and Skin Cancer Center
• Hoboken Univ Med Ctr
• Orthodontia Studio
• CTOR
• Octapharma USA
• Care Access - Hoboken /ID# 264066
• GSK Investigational Site

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Care Access Research /ID# 218476?

Care Access Research /ID# 218476 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Care Access Research /ID# 218476 conducted?

Care Access Research /ID# 218476 has 1 clinical trials on record. Their work covers Atopic Dermatitis.

Is Care Access Research /ID# 218476 accredited by Crixeo Clinical Trials?

Care Access Research /ID# 218476 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Care Access Research /ID# 218476?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.